Anti-CD19 mRNA delivered CAR T cell therapy(Capstan Therapeutics)

N/A

Report date: 2024/03/27 17:50:10

Base Information

Drug NameAnti-CD19 mRNA delivered CAR T cell therapy(Capstan Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCapstan Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCapstan Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A